SYNERCAN

Technology

One platform: drugs that enhance each other, delivered in nanoemulsions

We combine drug repurposing, pharmacological synergy and nanomedicine to reach effective therapies faster and with less risk.

01

Repurposing

We use drugs already approved for other indications. Having already met safety criteria, they compete on efficacy rather than safety, and dramatically cut the cost and time to reach patients.

02

Synergy

We combine chemotherapy drugs with molecules that enhance their action. This lowers the effective chemotherapy dose and, with it, the toxicity for the patient.

03

Nanoemulsions

We deliver our combinations in biocompatible nanoemulsions that help the treatment reach its target and increase its efficacy.

Lead program

Osteosarcoma

One of the most common paediatric cancers and among the most resistant to chemotherapy. Our therapy combines a chemotherapy agent with a molecule that enhances its effect: a synergy that significantly reduces the effective dose and toxicity.

Histological section of tumour tissue

Greater tumour reduction

In in vivo models, the combination enhanced the reduction in tumour volume.

Less toxicity

Lower effective chemotherapy dose and fewer toxic effects.

Almost no metastases

Near-complete suppression of lung metastases in animal models.

Better when nanoencapsulated

In 3D models, the nanoemulsion treatment outperformed its free form.

Pipeline

One platform, several indications

OsteosarcomaLead program
In vivo proof of concept
ChondrosarcomaCombination therapy in nanoemulsion
In vitro synergy · next phase in vivo
Acute lymphoblastic leukaemiaCombination therapy
Synergistic effect in vitro
Inflammatory diseasesArthritis and cartilage
Exploratory

Want to help bring these therapies to the clinic?

Get in touch